EP4746868A2 - Auf proteolyse gerichtete chimäre zur behandlung von neurodegeneration - Google Patents

Auf proteolyse gerichtete chimäre zur behandlung von neurodegeneration

Info

Publication number
EP4746868A2
EP4746868A2 EP24843911.9A EP24843911A EP4746868A2 EP 4746868 A2 EP4746868 A2 EP 4746868A2 EP 24843911 A EP24843911 A EP 24843911A EP 4746868 A2 EP4746868 A2 EP 4746868A2
Authority
EP
European Patent Office
Prior art keywords
alkyl
independently selected
conjugate
haloalkyl
haloalkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24843911.9A
Other languages
English (en)
French (fr)
Inventor
Changning Wang
Stephen Neil GOMPERTS
Ping Bai
Tim Bartels
Vikram Khurana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
The Brigham and Women's Hospital Inc
General Hospital Corp
Original Assignee
UCL Business Ltd
The Brigham and Women's Hospital Inc
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCL Business Ltd, The Brigham and Women's Hospital Inc, General Hospital Corp filed Critical UCL Business Ltd
Publication of EP4746868A2 publication Critical patent/EP4746868A2/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
EP24843911.9A 2023-07-18 2024-07-17 Auf proteolyse gerichtete chimäre zur behandlung von neurodegeneration Pending EP4746868A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363527513P 2023-07-18 2023-07-18
PCT/US2024/038386 WO2025019590A2 (en) 2023-07-18 2024-07-17 Proteolysis targeting chimeras for treating neurodegeneration

Publications (1)

Publication Number Publication Date
EP4746868A2 true EP4746868A2 (de) 2026-05-27

Family

ID=94282589

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24843911.9A Pending EP4746868A2 (de) 2023-07-18 2024-07-17 Auf proteolyse gerichtete chimäre zur behandlung von neurodegeneration

Country Status (3)

Country Link
EP (1) EP4746868A2 (de)
CN (1) CN122249207A (de)
WO (1) WO2025019590A2 (de)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2702950A1 (en) * 2007-10-16 2009-04-23 Northeastern University Methods and compounds for modulating cannabinoid activity
US8648079B2 (en) * 2011-10-07 2014-02-11 Takeda Pharmaceutical Company Limited Heterocyclic compounds
US11707452B2 (en) * 2018-08-20 2023-07-25 Arvinas Operations, Inc. Modulators of alpha-synuclein proteolysis and associated methods of use
US20240002458A1 (en) * 2020-11-09 2024-01-04 St. Jude Children's Research Hospital Novel vhl small molecule probes
US20240293557A1 (en) * 2021-06-08 2024-09-05 University Of Maryland, Baltimore Proteolysis targeting chimeras and methods of use thereof

Also Published As

Publication number Publication date
WO2025019590A3 (en) 2025-04-03
CN122249207A (zh) 2026-06-19
WO2025019590A2 (en) 2025-01-23

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20260306

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR